Abstract 1661P
Background
Pancreatic cancer (PC) has a high mortality rate and treatment options remain very limited. While there is great appeal in improving patient outcomes by implementing precision medicine in this disease, there are significant barriers including challenges in accessing adequate biopsy material to analyse. Endoscopic ultrasound (EUS) biopsy is a common diagnostic procedure and often the only source of tissue for patients with PC, but the utility of these biopsies to provide high quality biopsy material for clinically relevant molecular profiling remains lacking.
Methods
This study enrolled 135 patients undergoing diagnostic EUS biopsy as standard of care in PC to perform molecular analysis using a commercial 500-gene panel which also provides data on clinically relevant gene fusions, tumour mutation burden (TMB) and microsatellite status. No interventions were provided, but data was analysed and discussed at a Molecular Tumour Board meeting and relevant findings fed back to treating oncologists. Patients were followed for treatment data and survival.
Results
7 patients were unable to be analysed due to a lack of available biopsy material (n=2), withdrawal of consent (n=1) or inadequate QC metrics (n=4). We detected common oncogenes at expected frequencies, with KRAS in 114 (90%), TP53 in 85 (66%), SMAD4 in 13 (10%) and CDKN2A in 11 (9%). Targetable molecular findings were detected in 28 (22%), with RNF43 variants in 11 (9%), high TMB in 10 (8%), BRCA1/2 mutations in 4 (3%), BRAF V600E mutations in 2 (2%), CHEK2 mutation in 1 (1%) and BARD1 mutation in 1 (1%). No microsatellite instability was detected. Median TMB in this cohort was low, as expected, at 3.1Mut/Mb. However, of the 10 patients with high TMB (>10Mut/Mb), 5 of these had markedly hypermutated profiles (TMB >150Mut/Mb). To date, 8 patients (6%) have commenced targeted therapies and survival follow up is ongoing.
Conclusions
This study validates EUS as a reliable and accurate source of biopsy material for clinically relevant tumour profiling and adds to the body of literature highlighting the potential to improve patient outcomes in PC through routine genomic analysis, despite the many challenges.
Clinical trial identification
ACTRN12620000762954.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Victorian Cancer Agency.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1665P - Prognostic impact of diabetes and antidiabetic medication in pancreatic cancer patients
Presenter: Alexander Friedrich
Session: Poster session 22
1667P - Clinical and molecular features of young onset pancreatic adenocarcinoma
Presenter: Maxime Remond
Session: Poster session 22
1668P - Prevalence and management of pancreatic ductal adenocarcinoma (PDAC) over a decade in France: A population-based study
Presenter: Léo Mas
Session: Poster session 22
1670P - Tumoral and non-tumoral thrombosis associated with pancreatic ductal adenocarcinoma (PDAC): Survival impact, assessment of predictive scales and rethrombosis
Presenter: Alejandra Cardozo
Session: Poster session 22
1671P - Treatment patterns and efficacy in patients (pt) with pancreatic cancer (PC) from the Spanish RETUD registry
Presenter: Teresa Macarulla
Session: Poster session 22
1673P - Trajectories of immune-related serum proteins and quality of life in patients with pancreatic and other periampullary cancer: The champ study
Presenter: Sofie Olsson Hau
Session: Poster session 22
1674P - VILP registry of patients with metastatic pancreatic cancer treated with pegylated liposomal irinotecan plus 5-fluoroucil and leucovorin in the Czech Republic
Presenter: Stanislav Batko
Session: Poster session 22
1675P - Diagnostic performance of blood-based DNA methylation assay using epigenetic-specific peptide nucleic acid in pancreatic adenocarcinoma
Presenter: Hongsik Kim
Session: Poster session 22
1676P - Clinical outcomes of first-line chemotherapy in locally advanced and metastatic pancreatic adenocarcinoma patients: Real-world experience
Presenter: Nunticha Umpawan
Session: Poster session 22